Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FDMT vs BEAM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FDMT Captures Overall Composite Edge (42.1 HOLD vs 45.9 HOLD), While BEAM Leads 3–2 on Growth & Valuation Pillars

FDMT Overall Winner 6-Pillar Tally: FDMT 2 – 3 BEAM (1 Tie) Matrix Metrics: FDMT 3 – 5 BEAM

As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) captures the overall head-to-head institutional edge over Beam Therapeutics Inc. (BEAM) on higher Unified Composite conviction (42.1/100 HOLD vs. 45.9/100 HOLD) after splitting the core matrix 3–5 (led by Valuation Multiples, Balance Sheet & Cash Flow), while BEAM wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus BEAM at $21.29 (N/M Forward P/E, -267.7% operating margin).

  • Composite vs. Pillar Nuance: While BEAM currently prints a higher short-term Unified Composite Score (45.9/100 HOLD vs. FDMT 42.1/100 HOLD), FDMT captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-222.7% vs. -267.7% operating margin) and revenue trajectory (+4505.6% vs. -96.8% YoY).
  • Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile BEAM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FDMT vs BEAM
FDMT NASDAQ Head-to-Head Winner
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 21.0 Fund 54.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $12.12 · SMA50: $13.08
BEAM NASDAQ
Beam Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$21.29
-6.75% 1D
Market Cap $2.4B
TTM Revenue $147M
Forward P/E N/M
Beta / 30D Vol 2.24β · 86% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 30.0 Fund 52.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 37
RSI-14: 37.3 · SMA20: $25.54 · SMA50: $24.99

6-Pillar Scorecard Institutional Category Breakdown (FDMT 2 – 3 BEAM)

Columns: Metric · FDMT · BEAM
1. Valuation Multiples FDMT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.6x 16.8x
2. Growth & Scale BEAM
Revenue Growth (YoY) +4505.6% -96.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $96M $147M
Market Cap $669.3M $2.4B
3. Profitability & Quality BEAM
Gross Margin N/A N/A
Operating Margin -222.7% -267.7%
Net Profit Margin -208.6% -73.9%
Return on Equity (ROE) -56.7% -11.3%
4. Balance Sheet & Cash Flow FDMT
Cash Generation (TTM) -$156M -$398M
Cash Flow Margin N/A N/A
Net Cash / Leverage $31M Net Cash $31M Net Debt (0.26x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BEAM
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 82.4% (10th %ile) 66.0% (42nd %ile)
Put/Call OI Skew 5.16x (Put-Skewed) 0.47x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FDMT (3) vs BEAM (5)
Institutional Metric FDMT BEAM Criterion Row Edge
Market Capitalization
Scale
$669.3M $2.4B Larger Scale BEAM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+4505.6% -96.8% Higher Growth FDMT
Operating Margin (TTM)
Profitability
-222.7% -267.7% Higher Margin FDMT
Net Profit Margin
Profitability
-208.6% -73.9% Higher Margin BEAM
Return on Equity (ROE)
Capital Efficiency
-56.7% -11.3% Higher ROE BEAM
52-Week Range Position
Momentum
47% ($7–$17) 6% ($20–$38) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
1.89β · 90% Vol 2.24β · 86% Vol Lower Realized Risk BEAM
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 45.9 / 100 (HOLD) Higher Composite BEAM
Trailing 12M Revenue (USD)
Operating Scale
$96M $147M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.6x EV/Rev N/M PEG · 16.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$156M ($31M Net Cash) -$398M ($31M Net Debt (0.26x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FDMT +5.25 pp
FDMT: -4.04% · BEAM: -9.29%
3M Horizon BEAM +0.99 pp
FDMT: -20.86% · BEAM: -19.87%
6M Horizon FDMT +59.86 pp
FDMT: +39.27% · BEAM: -20.59%
1Y Horizon FDMT +15.04 pp
FDMT: +13.33% · BEAM: -1.71%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FDMT Revenue BEAM Revenue FDMT Op. Margin BEAM Op. Margin Margin Leader
FY2019 $10M $0M -729.4% -417522.2% FDMT
FY2020 $10M $0M -424.0% -553166.7% FDMT
FY2021 $20M $50M -395.5% -757.0% FDMT
FY2022 $0M $60M -3516.5% -555.6% BEAM
FY2023 $20M $380M -544.6% -46.7% BEAM
FY2024 $0M $60M -507678.4% -654.3% BEAM
FY2025 $90M $140M -187.2% -274.6% FDMT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BEAM BREAKDOWN
103d in phase · OBV DISTRIBUTION
Current IV 66.0%
IV Percentile 42nd %ile
Put/Call OI Skew 0.47x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BEAM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BEAM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4B market capitalization and -267.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FDMT vs BEAM Key Questions & Quantitative Answers

As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) captures the overall head-to-head institutional edge over Beam Therapeutics Inc. (BEAM) on higher Unified Composite conviction (42.1/100 HOLD vs. 45.9/100 HOLD) after splitting the core matrix 3–5 (led by Valuation Multiples, Balance Sheet & Cash Flow), while BEAM wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus BEAM at $21.29 (N/M Forward P/E, -267.7% operating margin). Composite vs. Pillar Nuance: While BEAM currently prints a higher short-term Unified Composite Score (45.9/100 HOLD vs. FDMT 42.1/100 HOLD), FDMT captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-222.7% vs. -267.7% operating margin) and revenue trajectory (+4505.6% vs. -96.8% YoY). Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile BEAM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BEAM leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with BEAM at -96.8% YoY revenue growth and +0.0% YoY earnings growth on $147M TTM revenue (N/A gross margin, -267.7% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), FDMT cumulative revenue shifted +800.0% while BEAM shifted +180.0%. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BEAM.

FDMT screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas BEAM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus BEAM (-11.3% ROE) capital efficiency.

In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, BEAM carries 66.0% implied volatility (42nd %ile, Balanced (25th–60th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.